Skip to main content
SpringerLink
Log in

Phase II evaluation of merbarone in renal cell carcinoma

  • Phase II Studies
  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The Southwest Oncology Group (SWOG) studied the response rate and toxicity of merbarone (1,000 mg/m2 IV continuous infusion days 1–5, q 21 days) in patients with advanced metastatic renal cell carcinoma. Among 36 eligible patients, there was one partial response for a response rate of 3% (95% C.I. 0.1–15%). There were no mixed responses. There were no treatment related deaths or adverse drug reactions. Significant anemia, diarrhea, and hypercalcemia were observed. Mild to moderate degrees of malaise/fatigue/lethargy, dizziness/vertigo, hyperglycemia, creatinine increase, nausea, vomiting, weight loss, pedal edema, dyspnea, and granulocytopenia were noted. Merbarone does not have significant activity as a single agent in advanced renal cell carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. National Cancer Institute, Clinical brochure merbarone NSC-336628, October 1985

  2. Cooney DA, Covery JM, Kang GJ, Dalai M, McMahon JB, Johns DG: Initial mechanistic studies with merbarone (NSC-336628). Biochem Pharmacol 33:3395, 1985

    Google Scholar 

  3. Drake FH, Hofmann GA, Mong S, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR, Mirabelli CK:In vitro and intracellular inhibition of topoisomerase II by the antitumor agent Merbarone. Cancer Res 49:2578–2583, 1989

    Google Scholar 

  4. Supko JG, Grever MR, Balcerzak SP, Kraurt EH, Staubus AE, Malspeis L: Spectral characterization and quantitation of the principal metabolites of merbarone (NCS-336628) in the urine of patients. AACR (abstr. 751), 1988

  5. Warrell RP, Dimaggio JJ, Muindi J, Young CW, Yaldei S, Balzer L: Phase I clinical pharmacologie study of merbarone. AACR (abstr. 749), 1988

  6. Grever MR, Kraut EH, Supko JG, Trewyn RW, Starbus AE, Malspeis L: Merbarone (NSC-336628) enhances the urinary excretion of uric acid of cancer patients. AACR (abstr. 752), 1988

Download references

Author information

Authors and Affiliations

  1. Loyola University Medical Center, Maywood, Illinois

    Robert C. Flanigan

  2. Albuquerque VAMC, Albuquerque, New Mexico

    Joseph H. Saiers

  3. Southwest Oncology Group Statistical Center, Seattle, Washington

    Michael Wolf & Brent Blumenstein

  4. Ohio State University, Columbus, Ohio

    Eric H. Kraut

  5. University of New Mexico School of Medicine, Albuquerque, New Mexico

    Anthony Y. Smith

  6. University of Colorado, Denver, Colorado, USA

    E. David Crawford

Authors
  1. Robert C. Flanigan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph H. Saiers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric H. Kraut
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anthony Y. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Brent Blumenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. David Crawford
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flanigan, R.C., Saiers, J.H., Wolf, M. et al. Phase II evaluation of merbarone in renal cell carcinoma. Invest New Drugs 12, 147–149 (1994). https://doi.org/10.1007/BF00874446

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874446

Key words

Search

Navigation